N/A N=8,790 Streptococcus Pneumonia: Effects of PCV13 on Pneumococcal Carriage
Nasopharyngeal Carriage of S. Pneumoniae
Primary: Nasopharngeal Colonization With PCV13 S. Pneumoniae — 20; 31; 166; 137 Participants — p=<0.05
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=9,707 Nasopharyngeal Streptococcus Pneumoniae Carriage
Streptococcus Pneumoniae Infections
Primary: Percentage of Participants With Carriage of Streptococcus Pneumoniae in Nasopharynx — 12.6 Percentage of Participants
Phase 3 N=172 Vaccination Course in Primed Children and Age-matched Unprimed Children With Pneumococcal Vaccine GSK1024850A
Infections, Streptococcal
Primary: Antibody Geometric Mean Concentrations (GMCs) Against the Vaccine Pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F in the Unprimed Group — 0.06; 0.04…
Phase 3 N=1,112 Safety and Immunogenicity Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine.
Infections, Streptococcal
Primary: Number of Subjects With Rectal Temperature Above (>) 39.0 Degrees Celsius (°C) Post Booster Between the Synflorix-Synflorix and Prevenar-Prevenar Groups — 24; 7…
Phase 3 N=262 Study Evaluating Antibody Response Of 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) 24 Months After Toddler Dose.
13-valent Pneumococcal Vaccine · Immunization · Safety
Primary: Serotype-specific Pneumococcal Immunoglobulin G (IgG) Geometric Mean Concentration (GMC) 1 Month After Single Dose of 13 Valent Pneumococcal Conjugate (13vPnC) Vaccine…
Phase 3 N=750 Prophylactic Antipyretic Treatment in Children Receiving Booster Dose of Pneumococcal Conjugate Vaccine GSK1024850A
Infections, Streptococcal
Primary: Number of Subjects Reported With Core Fever (Rectal Temperature) Greater Than or Equal to (≥) the Cut-off — 64; 14; 100; 16 Participants
Phase 3 N=443 Long-term Follow-up Study of Children Previously Primed With GSK Pneumococcal Vaccine (GSK1024850A) and of Unprimed Children
Infections, Streptococcal
Primary: Antibody Concentrations Against Vaccine Pneumococcal Serotypes — 1.24; 7.63; 4.52; 12.95 μg/mL
Phase 3 N=484 Primary and Booster Vaccination Study With a Pneumococcal Vaccine in HIV Infected, HIV Exposed Uninfected and HIV Uninfected Children 6 to 10 Weeks of Age.
Infections, Streptococcal
Primary: Number of Subjects With Anti-pneumococcal Vaccine Serotype Antibody Concentrations Equal to or Above 0.20 Microgram Per Millilitre (µg/mL). — 69; 90; 93; 94 Participants
Phase 2 N=120 Impact of GSK Biologicals' 2189242A Vaccine on Nasopharyngeal Carriage, Safety & Immunogenicity in Children & Infants
Infections, Streptococcal
Primary: Number of Subjects With Any and Grade 3 Solicited Local Symptoms and Grade 3 Solicited Local Symptoms With Relationship to Vaccination - For Step 1/Cohort 1 Subjects…
Phase 3 N=6,177 Impact on Carriage, Acute Otitis Media, Immuno & Safety of GSK Biologicals' Pneumococcal Conjugate Vaccine 1024850A
Infections, Streptococcal · Streptococcus Pneumoniae
Primary: Person Year Rate as Regards Subjects With Culture-confirmed IPD Due to Any of the 10 Pneumococcal Vaccine Serotypes. In Children Starting Vaccination Within 7 Months of…
N/A N=3,641 Prevalence of Nasopharyngeal Carriage of Streptococcus Pneumoniae in Healthy Children of 12-18 Months in 6 Cities, China
Streptococcus Pneumoniae Infections
Primary: Percentage of Participants With Nasopharyngeal Carriage of Streptococcus Pneumoniae — 12.5; 7.2; 16.6; 9.3 percentage of participants
Phase 2 N=66 A Trial To Evaluate A Multivalent Pneumococcal Conjugate Vaccine In Healthy Adults 50-85 Years Of Age
Pneumococcal Infections
Primary: Stage 1: Percentage of Participants With Local Reactions Within 14 Days After Vaccination — 2.9; 12.5; 2.9; 6.3 percentage of participants
Phase 3 N=303 Safety and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) in HIV-Infected Subjects 6 Years of Age or Older Who Are Naive to Pneumococcal Vaccine
HIV Infections · Pneumococcal Infections
Primary: Geometric Mean Fold Rise (GMFR) for Serotype-Specific Pneumococcal Immunoglobulin G (IgG) Antibody From 1 Month After 13vPnC Dose 2 to 1 Month After 13vPnC Dose 3 in All…
Phase 3 N=603 Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants
Vaccines, Pneumococcal Conjugate Vaccine
Primary: Percentage of Subjects Achieving Predefined Antibody Level ≥1:8 for Meningococcal C Serum Bactericidal Assay (SBA) in the 13vPnC Group Relative to 7vPnC Group After 2…
Phase 3 N=780 Co-administration of Pneumococcal Conjugate Vaccine With DTPa-IPV-Hib Versus Co-administration With DTPa-HBV-IPV/Hib
Infections, Streptococcal
Primary: Antibody Concentrations Against Pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F (Anti-1, -4, -5, -6B, -7F, -9V, -14, -18C, -19F and -23F) - Primary…